The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | NHL following treatment for classical HL
Dennis Eichenauer, MD, University Hospital of Cologne, Cologne, Germany, talks on the incidence of non-Hodgkin lymphoma (NHL) following treatment for classical Hodgkin lymphoma (HL) as evaluated in a retrospective analysis from the German Hodgkin Study Group. In this analysis, it was observed that NHL after classical HL is a rare event primarily affecting older individuals and often resulting in the patients’ death. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
